Blue Apron Holdings (APRN) “Hold” Rating Reiterated by Analysts at RBC Capital; With $4.0 Target; Meridian Bioscience (VIVO) Sentiment Is 1.37

February 14, 2018 - By Adrian Mccoy

Among 16 analysts covering Blue Apron (APRN), 4 have Buy rating, 1 Sell and 11 Hold. Therefore 25% are positive. Blue Apron has $14 highest and $2 lowest target. $6.77’s average target is 97.66% above currents $3.425 stock price. Blue Apron had 35 analyst reports since July 11, 2017 according to SRatingsIntel. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, November 2. As per Monday, August 21, the company rating was maintained by Oppenheimer. As per Friday, August 11, the company rating was downgraded by Citigroup. The firm has “Buy” rating given on Thursday, August 10 by Canaccord Genuity. As per Tuesday, October 24, the company rating was maintained by SunTrust. The rating was downgraded by Stifel Nicolaus to “Hold” on Friday, August 18. The firm earned “Buy” rating on Tuesday, August 8 by RBC Capital Markets. The stock has “Equal-Weight” rating by Barclays Capital on Monday, December 4. The firm earned “Underweight” rating on Friday, November 3 by Barclays Capital. The stock of Blue Apron Holdings, Inc. (NYSE:APRN) earned “Neutral” rating by Goldman Sachs on Thursday, August 10.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $600.77 million. The firm operates through Diagnostics and Life Science divisions. It has a 27.84 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

Brown Capital Management Llc holds 0.96% of its portfolio in Meridian Bioscience, Inc. for 5.49 million shares. Sg Capital Management Llc owns 366,117 shares or 0.57% of their US portfolio. Moreover, Clark Estates Inc Ny has 0.54% invested in the company for 227,000 shares. The New York-based Lucus Advisors Llc has invested 0.49% in the stock. Connors Investor Services Inc, a Pennsylvania-based fund reported 201,852 shares.

The stock increased 0.71% or $0.1 during the last trading session, reaching $14.2. About 51,546 shares traded. Meridian Bioscience, Inc. (VIVO) has declined 26.84% since February 14, 2017 and is downtrending. It has underperformed by 43.54% the S&P500.

Since January 1, 0001, it had 1 buy, and 0 sales for $14,750 activity.

The stock increased 2.24% or $0.075 during the last trading session, reaching $3.425. About 1.37M shares traded. Blue Apron Holdings, Inc. (APRN) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: